Akt
The Ser/Thr kinase AKT, also known as protein kinase B (PKB) has been the focus of tens of thousands of studies in diverse fields of biology and medicine. Activation of PI3K by extracellular stimuli results in activation of AKT in virtually all cells and tissues. The canonical pathway leading to AKT activation is initiated by the stimulation of receptor tyrosine kinases (RTK) or G protein coupled receptors (GPCR) leading to plasma membrane recruitment and activation of one or more isoforms of the class I PI3K family.Activation of PI3K results in the phosphorylation of two key residues on AKT1, T308 in the activation, or T-loop, of the catalytic protein kinase core, and S473 in a C-terminal hydrophobic motif. Phosphorylation of both residues is required for maximal activation of the kinase.
Regulation also occurs on corresponding residues in AKT2 (T309 and S474) and AKT3 (T305 and S472). In addition to signal termination by lipid phosphatases such as PTEN and INPP4B, two critical protein phosphatases function to directly inactivate AKT. There have been many advances in our knowledge of the upstream regulatory inputs into AKT, key multifunctional downstream signaling nodes (GSK3, FoxO, mTORC1), which greatly expand the functional repertoire of Akt, and the complex circuitry of this dynamically branching and looping signaling network that is ubiquitous to nearly every cell in our body. Mouse and human genetic studies have also revealed physiological roles for the AKT network in nearly every organ system. The comprehension of AKT regulation and functions is particularly important given the consequences of AKT dysfunction in diverse pathological settings, including developmental and overgrowth syndromes, cancer, cardiovascular disease, insulin resistance and type-2 diabetes, inflammatory and autoimmune disorders, and neurological disorders.
References
1.Manning BD, et al. Cell. 2017 Apr 20;169(3):381-405. doi: 10.1016/j.cell.2017.04.001.
Regulation also occurs on corresponding residues in AKT2 (T309 and S474) and AKT3 (T305 and S472). In addition to signal termination by lipid phosphatases such as PTEN and INPP4B, two critical protein phosphatases function to directly inactivate AKT. There have been many advances in our knowledge of the upstream regulatory inputs into AKT, key multifunctional downstream signaling nodes (GSK3, FoxO, mTORC1), which greatly expand the functional repertoire of Akt, and the complex circuitry of this dynamically branching and looping signaling network that is ubiquitous to nearly every cell in our body. Mouse and human genetic studies have also revealed physiological roles for the AKT network in nearly every organ system. The comprehension of AKT regulation and functions is particularly important given the consequences of AKT dysfunction in diverse pathological settings, including developmental and overgrowth syndromes, cancer, cardiovascular disease, insulin resistance and type-2 diabetes, inflammatory and autoimmune disorders, and neurological disorders.
References
1.Manning BD, et al. Cell. 2017 Apr 20;169(3):381-405. doi: 10.1016/j.cell.2017.04.001.
Cytoskeleton/Cell Adhesion Molecules
Akt
-
YS-67
catalog no : M37328
cas no: 2761327-15-3
YS-67 is an orally available, selective and potent EGFR inhibitor with antitumor activity, inhibits p-EGFR and p-AKT, and inhibits the proliferation of A549, PC-9, and A431 cells. -
Xentuzumab
catalog no : M36725
cas no: 1417158-65-6
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours. -
Akt3 degrader 1
catalog no : M36618
cas no: 2836342-69-7
Akt3 degrader 1 is a specific Akt3 degrader with anticancer and antiproliferative activity that inhibits tumor growth in mice.Akt3 degrader 1 is used in the study of non-small cell lung cancer and pancreatic cancer. -
ZINC00640089
catalog no : M36484
cas no: 667880-11-7
ZINC00640089 is a selective lipid carrier protein-2 (LCN2) inhibitor. ZINC00640089 inhibited cell proliferation and cell viability, and reduced AKT phosphorylation in SUM149 cells. ZINC00640089 can be used to study inflammatory breast cancer (IBC). -
Hu7691 free base
catalog no : M35148
cas no: 2241232-43-7
Hu7691 free base is an orally active, potent, and selective Akt inhibitor with anti-proliferative and neurogenic effects on various neuroblastoma cell lines.